Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says

This article was originally published in The Gray Sheet

Executive Summary

Adaptive device clinical trials, where study is designed in anticipation of midstream changes, are the focus on a new FDA draft guidance. Adaptive trials can reduce the duration and cost of a study without undermining its integrity, but the practice should be applied with caution, FDA says.


Related Content

Adaptive Study Design OK For Single-Arm Trials, FDA Says
Science Evolution At FDA ‘Transformative,’ Advisors Say
Can Basket Trials Boost Use Of Bayesian Statistics?
Single-Arm Studies Can Have Adaptive Designs, Industry Tells FDA
Replacing Test Subjects With Computer Models Will Take Cooperation
Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice
Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts